High Growth Tech Stocks In Sweden Embracer Group And Two More

Sweden's tech sector has been gaining attention amid a backdrop of strong performance in global growth stocks, with technology shares outpacing their value counterparts significantly. As markets navigate economic indicators and interest rate changes, identifying high-growth opportunities becomes crucial for investors looking to capitalize on the evolving landscape. In this article, we will explore three standout tech stocks in Sweden, starting with Embracer Group. Understanding what makes these companies promising involves examining their innovative capabilities and market positioning within the current economic environment.

Top 10 High Growth Tech Companies In Sweden

Name	Revenue Growth	Earnings Growth	Growth Rating
Truecaller	20.32%	21.61%	★★★★★★
Fortnox	20.18%	22.60%	★★★★★★
Xbrane Biopharma	53.90%	118.02%	★★★★★★
Yubico	20.52%	42.35%	★★★★★★
Bonesupport Holding	33.76%	31.20%	★★★★★★
Scandion Oncology	40.71%	75.34%	★★★★★★
Hemnet Group	20.13%	25.41%	★★★★★★
Skolon	31.76%	121.72%	★★★★★★
BioArctic	42.38%	98.40%	★★★★★★
KebNi	34.75%	86.11%	★★★★★★

Click here to see the full list of 80 stocks from our Swedish High Growth Tech and AI Stocks screener.

Let's review some notable picks from our screened stocks.

Embracer Group (OM:EMBRAC B)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Embracer Group AB (publ), along with its subsidiaries, develops and publishes PC, console, mobile, VR, and board games for the global market and has a market cap of SEK35.13 billion.

Operations: Embracer Group AB generates revenue primarily from Tabletop Games (SEK14.65 billion), PC/Console Games (SEK13.10 billion), Mobile Games (SEK5.87 billion), and Entertainment & Services (SEK6.13 billion). The company focuses on a diverse portfolio across various gaming platforms, catering to a global audience.

Embracer Group, despite recent challenges, shows notable resilience in the tech sector. With a forecasted annual earnings growth of 103.8% and expected revenue growth of 3.3%, it outpaces the Swedish market's average. The company reported SEK 7,933 million in sales for Q1 2024 but faced a net loss of SEK 2,183 million compared to last year's net income of SEK 2,250 million. Their R&D expenses reflect significant investment into future innovations and product development.

• Delve into the full analysis health report here for a deeper understanding of Embracer Group.

• Learn about Embracer Group's historical performance.

Paradox Interactive (OM:PDX)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Paradox Interactive AB (publ) develops and publishes strategy and management games for PC and consoles across various global regions, with a market cap of approximately SEK17.37 billion.

Operations: The company focuses on developing and publishing strategy and management games for PC and consoles, generating revenue primarily from computer graphics, which amounted to SEK2.48 billion. The market cap stands at approximately SEK17.37 billion.

Paradox Interactive, a prominent name in the gaming industry, is making substantial moves with recent expansions like "Friends & Foes" for Crusader Kings III and "Cosmic Storms" for Stellaris. Despite a 9.1% annual revenue growth forecast, its net income saw a significant drop to SEK 27.28 million from SEK 239.35 million last year. R&D expenses reflect their commitment to innovation, crucial for staying competitive in the evolving tech landscape; they spent SEK 167.4 million on non-recurring items impacting financial results over the last year.

• Unlock comprehensive insights into our analysis of Paradox Interactive stock in this health report.

• Understand Paradox Interactive's track record by examining our Past report.

Swedish Orphan Biovitrum (OM:SOBI)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Swedish Orphan Biovitrum AB (publ) is an integrated biotechnology company that researches, develops, manufactures, and sells pharmaceuticals in haematology, immunology, and specialty care across Europe, North America, the Middle East, Asia, and Australia with a market cap of SEK112.89 billion.

Operations: Swedish Orphan Biovitrum AB (publ) derives its revenue primarily from three segments: Hematology (SEK15.07 billion), Immunology (SEK7.49 billion), and Specialty Care (SEK1.15 billion). The company operates across Europe, North America, the Middle East, Asia, and Australia.

Swedish Orphan Biovitrum (Sobi) has shown notable advancements, particularly in its R&D efforts. With SEK 1.2 billion allocated to research and development in the last year, Sobi is committed to innovation, as evidenced by the promising Phase 3 VALIANT study results for pegcetacoplan. Revenue growth of 9.4% annually outpaces the broader Swedish market's forecast of 1%. Despite a dip in net profit margins from 15.5% to 9%, earnings are projected to grow at an impressive rate of 25.8% per year, reflecting strong future potential driven by their pipeline advancements and strategic initiatives in rare disease therapies.

• Click to explore a detailed breakdown of our findings in Swedish Orphan Biovitrum's health report.

• Evaluate Swedish Orphan Biovitrum's historical performance by accessing our past performance report.

Taking Advantage

• Delve into our full catalog of 80 Swedish High Growth Tech and AI Stocks here.
• Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
• Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.

Looking For Alternative Opportunities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com